Avidity Biosciences Inc (NASDAQ: RNA) on Tuesday, soared 3.06% from the previous trading day, before settling in for the closing price of $31.20. Within the past 52 weeks, RNA’s price has moved between $21.51 and $56.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 49.32%. The company achieved an average annual earnings per share of -32.24%. With a float of $111.14 million, this company’s outstanding shares have now reached $119.89 million.
Let’s determine the extent of company efficiency that accounts for 391 employees. In terms of profitability, gross margin is 87.81%, operating margin of -3477.44%, and the pretax margin is -2957.72%.
Avidity Biosciences Inc (RNA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Avidity Biosciences Inc is 7.55%, while institutional ownership is 104.10%. The most recent insider transaction that took place on Apr 01 ’25, was worth 163,486. In this transaction Chief Program Officer of this company sold 5,875 shares at a rate of $27.83, taking the stock ownership to the 50,554 shares. Before that another transaction happened on Mar 20 ’25, when Company’s Chief Medical Officer sold 9,578 for $31.06, making the entire transaction worth $297,491. This insider now owns 72,850 shares in total.
Avidity Biosciences Inc (RNA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -32.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.06% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Avidity Biosciences Inc (RNA) is currently performing well based on its current performance indicators. A quick ratio of 15.73 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 354.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.90, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -4.30 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Looking closely at Avidity Biosciences Inc (NASDAQ: RNA), its last 5-days average volume was 0.97 million, which is a drop from its year-to-date volume of 1.47 million. As of the previous 9 days, the stock’s Stochastic %D was 93.96%. Additionally, its Average True Range was 1.99.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 53.38%, which indicates a significant decrease from 99.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.81% in the past 14 days, which was lower than the 63.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.68, while its 200-day Moving Average is $37.77. However, in the short run, Avidity Biosciences Inc’s stock first resistance to watch stands at $32.68. Second resistance stands at $33.20. The third major resistance level sits at $34.20. If the price goes on to break the first support level at $31.15, it is likely to go to the next support level at $30.15. Now, if the price goes above the second support level, the third support stands at $29.63.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
Market capitalization of the company is 3.87 billion based on 120,212K outstanding shares. Right now, sales total 10,900 K and income totals -322,300 K. The company made 2,970 K in profit during its latest quarter, and -102,260 K in sales during its previous quarter.
